FCGRT and myasthenia gravis: Of note, the detection of any autoantibody specificity could provide an indication for the use of neonatal Fc receptor (FcRn) inhibitors, which work by blocking IgG recycling via the FcRn, thus reducing IgG half-life and which show potential for MG treatment in recent clinical trials (133).